Member Info for The_Paladin

For the time being a number of investors, like myself, are “locked in” to this investment. I am a small investor with 500K shares purchased too soon, as it turned out. I paid £14K for my shares, which are currently valued by my broker at less than £5K. I have no one to blame but myself for my misjudgement.

The investment is centred on the creativity and judgement of Prof Nag and his small teams. The U.K. directors are largely irrelevant bar one, who recently showed a willingness to commit through his investment.

The company is still very early stage. It is unlikely IMHO that it will gain traction to any extent this year, although I expect the share price to be higher than that within our current trading range by December. We still have some undecided and impatient investors on board, hence I anticipate more selling to follow. Some individuals will undoubtedly IMO transfer their capital elsewhere in search of quicker gains.

Much is currently being written about AI. A large number of contributors on LinkedIn have their views, many of them about AI’s use in authorship. It is impossible for me to make sense of this - the issue being too much information to make any sense of it all.

Prof Nag’s comments are clear and unambiguous. He has communicated his strategy recently. Soon he will need to elaborate on detail to add to CapAI’s credibility.

This won’t happen in the short term, but I am now hopeful of significant updates before the end of Q2, at which time a number of companies will enter a relatively quiet phase.

From a personal perspective, it would suit me if the share price were to remain at the current level for a further two months. Selfishly, this would allow me to position all my holding within my S&S ISA with minimal use of my next ISA allowance. This is a relatively short space of time. It is already two months since Richard Edwards’ resignation, and there has been little significant change to my investment since then.

Finally, I view my CapAI investment as one in which Prof Nag’s ability to get several AI applications of various genres to flourish is the only factor for investors to consider. His track record, work ethic, and commitment to his work may well make it happen?

GLA.

It would appear that a warrant seller / warrant sellers is/are still on board, although to a lesser extent than before? The only other alternatives are short term traders selling at the current level, or alternatively traders who regularly “gamble” on several small caps, and exit from some of these once they realise that it may take a considerable time before they achieve a return? The latter play the odds on several investments. Some actually manage to make a very good return when a certain percentage of their chosen companies substantially increase in value within their time frame.

My current strategy is the opposite to theirs. Although I am more confident than before following the last two RNS statements, it would suit me if the share price remained at the current levels for the next two months. This would enable me to top up my S&S ISA CapAI holding when the next ISA allowance is introduced.

Either way, I am more than happy to hold for the long term. Prof Nag will have a number of small ventures , which will be introduced under the CapAI umbrella later this year. If a percentage of these are successful, we will benefit greatly from the growth of our holdings. I should emphasise that the kind of growth that I am anticipating may well take a considerable time to come about?

Finally, it is always good to have directors who commit to their companies through their own investments. It would have been useful to have the two NEDs on board also. Perhaps they may choose to commit later?

GLA.

The question that troubles me is whether to buy more shares at the current price? I have succumbed in the past only to see the share price continue to drop. (The current dummy sell price for 200K shares is 1.092p).

I agree that we need an update as to how A42 is proceeding, but would prefer to wait for something significant rather than be offered the meaningless perfunctory notices so often issued by AIM companies.

We are not in the AIM category, although I am not so sure about our U.K. directors? The BOD change from Dec 17 still hasn’t been corrected on two Companies House listings nor on CapAI’s website. I notified the company a week ago, but did not receive a reply.

Whereas my future hopes rest exclusively with Prof Nag and his small teams, it would be good to see some interest from our U.K. directors. Jack Allardyce was quick enough to instantly list his CapAI credentials on LinkedIn on Dec 17, when it was annnounced by RNS. Apparently, he is not concerned that his status as a director doesn’t feature on the company website?

GLA.

For the time being, I am fully focused on Author 42, and look forward to the development of new tools within the application, as well as the improvement of the current repertoire. In addition, in the near future when A42 will exist in a multi-device subscription, enabling authors to continue their process across all their devices.

It is too soon to consider our prospective AI driven medically based apps, although the first one may well come to the fore later this year.

I am less happy with our U.K. directors. The company listings are not all correct at present. This is misleading for prospective investors doing their due diligence. It could all be quickly brought up to date. I emailed the company about it last week. I haven’t yet received a reply.

GLA.

Small_cap.

Thank you. I have e-mailed the company about the listings issues. I will share on this board should I receive a response, and if it proves to be relevant to investors.

Good suggestion, Thanks also for your earlier comment about the issue of a TR1 to accompany a significant number of sells. Apparently, Richard and Charlotte Edwards remain significantly invested in CapAI. Presumably, he left the BOD for personal reasons?

Small_cap.

It is interesting in that our directors, apparently, cannot be bothered to update this information? This is confusing for prospective investors doing their due diligence on the company. My previous links, which unfortunately do not lead to the relevant pages, state that on Feb 4, 2025, CapAI Ltd changed its name to Dukemount Capital?

I respect that in your opinion this is of no importance, but as an investor, I expect clarity in all documentation pertaining to companies in which I am invested. Anything that confuses an investor is simply not good enough.

Our former exec chair Richard Edwards yesterday commented on X about the referral to Prof Nag during the UK House of Commons Science Innovation and Technology Committee Biohacking Presentation on 20 January 2026:

“No surprise to see @RonjonNag referred to at this level. Will be following the tiny team @capAIplc closely as still have a very significant holding!”

Does this imply that he has been selling some of his holding recently? More interestingly, he is still listed as an active director of CapMedia and CapMedical. It is high time that our three U.K. directors did something about this IMHO. Are they actually doing anything to promote interest in CapAI? The jury is out on that issue until investors receive an update?

https://find-and-update.company-information.service.gov.uk/company/10058279/officers

https://find-and-update.company-information.service.gov.uk/company/12045749/officers

Mr. Edwards is also currently listed as a director of Dukemount Capital.

https://find-and-update.company-information.service.gov.uk/company/16201808/officers

Until recently, I was under the impression that Dukemount Capital no longer existed?

GLA.

A “big” seller has entered (or re- entered) our trading pattern which accounts for our recent relative share price downturn. I have my suspicions about this, and additionally concerning the very unfortunate protracted warrant sales following on from the continuous release of positive information to stimulate investor interest. In the absence of any evidence, I won’t comment any further.

As a relatively small investor (500K) shares, I am not looking to add for the time being. It will suit me should the share price remain at a low level until mid April. This would allow the transfer of CapAI share to my S&S ISA without sacrificing too much ISA allowance.

GLA.

Below is a list of some of the products that will compete with Author 42 when it is launched. It will be interesting to observe what professional reviewers will make of Author 42, when it becomes commercially available?

https://manuscriptreport.com/blog/best-ai-tools-for-authors

GLA

In the past, I didn't search for this information, and accepted what was reported at face value. There is no cumulative review information on the Author 42 platform. An AI search did not succeed in finding it, but provided a broad summary of the current outlook, which is useful. This will remain as the status quo for investors until we receive an update from the company, presumably during Q1 of the current year?

AI summary:

As of January 2026, Author42, a generative AI platform from capAI PLC (LSE: CPAI), is in its soft launch phase following a 12-week public beta that concluded in late 2025.

User and Market Sentiment

Reported Review Scores: Some search results for Author42 display a direct review score of 4.8/5 based on 847 reviews as of January 6, 2026. However, investors have noted difficulty in finding the primary source or the text of these specific reviews.

Beta Feedback: Early feedback from the beta phase has been described as positive, with users highlighting the tool's potential to help authors finish manuscripts up to 60% faster.

Investor Outlook: In share chat forums (e.g., London South East), sentiment is mixed. While some investors are optimistic about the platform’s high-growth niche and potential valuation (estimated between $58.8m and $8.82b depending on market capture), others remain skeptical due to recent share price volatility.

Core Capabilities: Designed primarily for non-fiction book creation, the platform includes features such as AI-powered "book blueprints," market demand validation, and "CLARA42," an AI for professional editing intelligence.

Subscription Model:

Free Plan: Available for basic access.

Paid Plans: Start at $20 per month.

Trial: Paid subscriptions typically include a 7-day free trial.

Future Updates: The company plans to introduce fiction-focused capabilities in early 2026 and expand into related media through "Creator42" and "Game42".

IMHO the latter tools may enable users to create content similar to that produced by Jayne Lytel?

GLA.

I wish I could offer some advice. No problems whatsoever on my home system. A MacBook Air M4 linked to a Swisscom Internet-Box-5 Pro router.

The tools already at my disposal are impressive indicating that a great deal of time and effort has gone into the system's development. We are still in a pre-launch phase and I shall be messaging Jayne Lytel and her team to wish them every success prior to the release date.

This is the first product in the CapMedia suite, with other complementary products to follow. Additionally, Author 42's capabilities will be refined and extended over the coming years. We have heard about its future application in writing novels, and the complementary phone app under development. Should the product prove to be as good as the early reviews suggest, this could be the start of a period of growth for the company's Capmedia arm. Jayne Lytel's online media output gives us some idea of what might be achievable?

https://www.runfromsunday.com

GLA

Good morning everybody.

I will begin by stating that I value most contributors' opinions on this forum. We suffer from the occasional visits of a few interlopers, such as the individual who regularly stated the share price spread to follow her/his earlier AI generated piece to sow seeds of doubt concerning CapAI's future prospects. These individuals are present on most boards for reasons best known to themselves. Other than these, I respect the and value POV of our regular contributors, although there may be major disagreement between them.

With regard to our directors, I am of the view that without Prof Nag's involvement, there would be no CapAI. As was recently shown when Richard Edwards our former Executive Chairman left the BOD, all the other current directors are replaceable.

One of my earlier posts stated that Prof Nag is a very busy individual. His LinkedIn profile shows that he currently holds THIRTEEN positions. Five of these are full time, including Adjunct Professor in Genetics in the School of Medicine at Stanford University, and Founder and President of R42 group. His role at CapAI is second in the list and is currently described as "Director CapAI Ltd. March 2025 - Present. Using AI to build AI" His diary has been somewhat busy of late. I am certain that his profile will be updated to reflect his increased CapAI involvement in due time.

The other directors are "standard" small cap company directors, all of which hold full time positions.

Sarah Jane Davey is a partner at EdwardsGreene. Richard Edwards is the firm's senior partner.

https://edwardsgreene.com/about/

Marcus Yeoman has been a director of Springtime Consultants Ltd since 2003.

https://find-and-update.company-information.service.gov.uk/company/04657744/officers

Last week, Jack Allardyce was appointed to the position of interim CFO at Harena, a mining company.

https://www.miningweekly.com/article/harena-appoints-new-interim-cfo-corporate-adviser-broker-2026-01-08

One task that awaits our three UK based part time directors is to update the following company listings.

https://find-and-update.company-information.service.gov.uk/company/10058279/officers

https://find-and-update.company-information.service.gov.uk/company/12045749/officers

The information for CapMedia (UK) Ltd, and CapMedical (UK) Ltd have not been updated since they were perfunctorily listed by Richard Edwards last year. On that subject, Dukemont Capital remains listed with Richard Edwards as its director.

https://find-and-update.company-information.service.gov.uk/company/16201808/officers

I firmly believe in the abilities of Prof Nag, Jayne Lyle and Claire Lu to drive forward and grow the Author 42 product. I remain unconvinced about the involvement of our UK directors following the share price decline we have suffered since the share price consolidation.

GLA.

The following link is concerned with Jack Allardyce’s latest interim CFO appointment yesterday. This confirms my suspicion that not one of our directors is giving CapAI anywhere near enough attention? Therein lies our problem.

https://m.miningweekly.com/article/harena-appoints-new-interim-cfo-corporate-adviser-broker-2026-01-08

In addition, Jayne Lytel’s online messages suggest that she has much of her focus on her other career as an author. Is there any wonder why our investment isn’t progressing as well as it might at the present time? Apart from Claire Lu, none of our personnel are doing much to promote this company. Surely this has to change?

GLA

My optimism remains undiminished, although I understand where ElMagico’s previous comment is coming from. I have followed Prof Nag’s LinkedIn messages recently, and it seems that he is involved with an appreciable number of micro companies. In addition, he is a popular contributor both as a regular enthusiastic speaker and panelist at medical conferences and other events. How much of his valuable time is assigned to CapAI is questionable? Prof Nag’s has emphasised a small lean team approach to product launches, with Jayne Lytel taking the lead at CapmMedia, and Claire Lu currently employed as a growth hacker for Author 42. Perhaps our concerns will be allayed when further developments are announced?

Additionally, there are three other directors assigned to the company which is still early stage?

https://find-and-update.company-information.service.gov.uk/company/07611240/officers

Allardyce was quick enough to add CapAI related skills to his LinkedIn profile on the day of his appointment. Has he achieved anything yet to justify his inclusion?

Richard Andrew Edwards is still listed as an active director in both of CapAI’s sub companies. This needs addressing if we are to be taken seriously.

It would be useful to know something about CapAI’s other directors namely Sarah Jane Davey (a close associate of Richard Edwards), and Marcus Yeoman. What do they bring to the table? They are both high level financial professionals, and investors need reassurance about the continued dire state of the share price, presumably as a consequence of the initial funding structure of the company, and the subsequent consolidation?

GLA.

Many thanks for the Author 42 review information. This is encouraging and I look forward to the company’s early stage feedback on the product’s uptake, and possibly some information on the ongoing review process? The application is still under development, and there appears to be considerably more to follow. As I see it, Claire Lu is doing her job well.

We may well see the emergence of some CapMedical development during H1. Prof Nag has well formed ideas on this aspect of CapAI, and we shall see what emerges?

https://www.linkedin.com/posts/ronjonnag_great-to-be-speaking-at-the-ai-insiders-event-ugcPost-7414134682960879617-8H5o

GLA

The Author 42 team are doing all they can to grant that Christmas wish. I received their latest e-mail (below) this morning. It is worth noting the range of support offered to authors (Home Screen of Author 42 website), and the fact that the mobile app, and the tools for writing novels are under rapid development for launch in early 2026.

Jane Lytel has an interesting perspective on e books.

“ If you're curious about how AI can elevate the art of storytelling, I invite you to explore my alpha site:

https://lnkd.in/eHBHcvBZ”

This is not of interest to me to me personally, but could have appeal for the younger generation, who manipulate multi media applications with ease. CapMedia was conceived to embrace all the different modes for presenting information.

If fully realised, CapAI’s future could be very bright indeed. The company’s initial funding initiatives were a disaster for the share price, but this has nothing to do with R42, whose product launches might well raise our spirits in the coming year?

Have a wonderful Christmas everyone.

“Hi there,

As the year winds down, we wanted to share a small holiday gift from us to you. We’re offering 25% off all Author42 yearly plans through January 3, 2026 — a great opportunity to begin the new year with clarity and momentum in your writing.

Starting a book is often about giving yourself space to think, shape ideas, and make steady progress, and this season can be a natural moment to do just that.

Wishing you a warm and restful holiday,”

https://author42.com/mobile-coming-soon

Perhaps my comments were unclear, but it was the persistent selling of warrants that predominantly caused the share price collapse.

This depletion is not a direct result of consolidation procedure, but rather a reflection of the market's negative assessment of the company's fundamentals that necessitated the consolidation in the first place.

is not a direct result of the accounting procedure, but rather a reflection of the market's negative assessment of the company's fundamentals that necessitated the consolidation in the first place.

I keep repeating myself, but like Prof Nag, I believe that Jane Lytel and Claire Lu are doing a fine job in gradually bringing Author 42 to the fore.

I am not a “ramper”, as some on this forum may think, but a long term investor, with a relatively small holding of 500K shares. These were purchased for around £14K, and werevalued at £6.5K when the markets closed last Friday afternoon.

Despite the aforementioned deficit, I remain optimistic that this investment will eventually recover and grow. I blame Richard Edwards and the two other financial professionals on the board at the time the initial arrangements for financing the company were made. They should have known better, and also anticipated the consequences of the share consolidation, which has resulted in our current depleted position.

On the positive side, the small Author 42 team mentioned above are ploughing on. I am regularly finding encouraging information (for authors) that Claire Lu has regularly deposited on LinkedIn, such as the comment below. Jane Lytel is more concerned with the overall growth and development of CapMedia, while Claire Lu is exclusively focused on Author 42. I don’t think that Prof Nag is directly involved, but will no doubt be monitoring all developments, and adding his own comments and suggestions when appropriate.

https://www.linkedin.com/posts/yanbing-lu_9-rare-book-writing-habits-that-will-transform-activity-7402746080871747584-R37a?utm_source=share&utm_medium=member_ios&rcm=ACoAADKsm2gBM4lh_W5cCfkUxRY7xooDWjyWccA

I don’t anticipate any further information until early 2026. When the beta phase finally ends, and the initial product is properly launched, suitable advertising will need to be put in place to ensure that potential subscribers are fully aware of the product, and what it can do. I am anticipating several improvements in the product itself, and its application on multiple devices over the coming year or so.

The above comments are my own humble opinions. I am always interested in the views of other thoughtful contributors.

My best wishes to everyone for the coming holiday. May good fortune smile on CapAI investors in the year to follow and beyond.

Having studied the Author 42 website, I tend to disagree with fellow contributors regarding the product's future viability. It is still in its Beta phase, and writing tools for fiction books are under development for launch in Beta format in early 2026. Prof Nag spends some of his time in academia, and will have assessed the needs of academics when writing their specialised non fiction books. The tools already in place are designed to provide for the academic author's requirements and assist them during the various components of their writing journey. Having worked alongside academic colleagues, who published textbooks, I am aware of how time consuming, and laborious the overall process can be. So many of my former colleagues took 5 - 10 busy years from starting work on their textbooks to finally completing them. Author 42 will enormously simplify the process, and is designed to assist the author throughout the various stages to publication, thereby reducing the stress induced at each step.

I appreciated the Author 42 Zoom meeting feedback posted earlier, and additionally from Clair Lu and Jane Lytel's comments since last September, I gather that they have their work cut out to inform potential authors of textbooks, popular non-fiction texts, as well as fiction in its various genres of, the advantages of using Author 42 as they work through the various stages of writing their book. They obviously need an advertising budget , as their current outreach on LinkedIn and elsewhere is far from sufficient and isn't reaching its intended users.

Author 42 is early stage, and we shall see how it progresses? Most investors here, myself included, are in agreement that future products launched through CapMedical may well have a wider appeal? Prof Nag's recent appearances as a guest speaker have been at conferences focused on medical matters, and he will no doubt be aware of the trends in medicine that will benefit the most from an AI input.

It has been a rough couple of months with this investment. Like so many of you, I am wondering whether Richard Edwards actions may have had anything to do with this? With Prof Nag as executive chair, and a restructured BOD, we can but hope for an improved outlook in the not too distant future? GLA.